Business Update" EBITDA is expected to be in line with guidance...

Business Update

" EBITDA is expected to be in line with guidance provided on 28 Feb, being EBITDA of up to
$2m on an underlying basis for FY23, before MEG write-downs, booked 31 December, 2022 of $6.9m

Cash for 30 June, 2023, was about $3.6m and debt about $7.0m, resulting in net debt of
about $3.4m, subject to audit

The Company has a solid balance sheet with cash for 30 June at $3.6m, which together
with unused banking facilities is about $5.0m. This balance, together with expected
ongoing positive operating cash flows, should be sufficient, now, to meet the businesses
current and future financing needs. Net debt position is around $3.4m on 30 June 2022 vs
$2.4m on 31 December 20 "

Can someone please explain to me how did we get into the position of Net Debt of 3.4 m ?

Was the Meg just a write-down ( on the books) or does CMP needs to refund Barrow
Neurological Institute the 6.9m, thank you ( someone ) in advance.